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Abstract 
Introduction: Typical bronchial carcinoid tumors are known for their relatively indolent 
behavior. There are only four reported cases in the medical literature describing typical 
bronchial carcinoids metastasizing to the brain. Little is known about the pathogenesis and 
presentation of this disease due to the very small patient population.  
Case Presentation: A 67-year-old Hispanic female presented to our hospital with a three-
week history of right arm numbness and poor coordination. Computed tomography (CT) 
with intravenous contrast of the brain and subsequent magnetic resonance imaging 
demonstrated multiple enhancing nodular densities throughout the brain. CT with 
intravenous contrast of the chest, abdomen, and pelvis revealed a left hilar mass and a 
medial left upper lobe mass. Histopathological findings were consistent with a 
neuroendocrine neoplasm of bronchial origin.  
Conclusion: Although metastases to the central nervous system are very frequent with small 
cell carcinomas, their presence is very uncommon in well-differentiated neuroendocrine 
tumors such as the one we present here. This case raises questions about whether these 
tumors contain biomarkers that might predict a more aggressive behavior and if these 
patients might benefit from aggressive interventions similar to those taken in small cell 
carcinomas, such as prophylactic cranial radiation. 
 
Introduction 
Accounting for approximately 1–2% of all lung malignancies in adults and roughly 
20–30% of all carcinoid tumors, bronchial carcinoids are neuroendocrine tumors made 
up of peptide- and amine-producing cells originating from the embryologic neural crest 
[1–4]. Carcinoids originate most commonly from the gastrointestinal tract, but can also  
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originate from the lung, thymus, and ovary. Bronchial carcinoids are broken down into 
typical and atypical tumors based on their pathologic tumor grade. Typical bronchial 
carcinoids are slow growing tumors that rarely metastasize, whereas atypical tumors 
metastasize early to the hilar or mediastinal nodes and are associated with a higher 
recurrence rate [5, 6]. The average age of adults diagnosed with typical and atypical 
bronchial carcinoid tumors is 45 and 55 years, respectively [7–9]. Typical and atypical 
bronchial carcinoids have five-year survival rates ranging from 87–100 to 30–95%, 
respectively [7, 10–24]. Bronchial carcinoids occur in 0.2–2 per 100,000 individuals per 
year, with a higher incidence among women and Caucasians [1–3, 25, 26]. A major risk 
factor for tumor development is smoking, which accounts for up to half of all bronchial 
carcinoids [27–31] and an even greater percentage of atypical carcinoids [5, 30]. 
Patients with the autosomal dominant syndrome of multiple endocrine neoplasia type 1 
(MEN1) are also at increased risk for bronchial carcinoid tumor development [27–31]. 
We report a case of a patient who presented with a typical carcinoid that 
metastasized to her brain. 
Case Presentation 
A 67-year-old Hispanic female presented to the emergency department complaining of a 3-week 
history of right arm numbness and poor coordination, during which eating, putting on makeup, and 
combing her hair had become increasingly difficult. Her past medical history was significant for well-
controlled essential hypertension and recently diagnosed Behçet’s syndrome. She smoked one pack a 
day for 37 years, quitting 15 years prior to the onset of symptoms. On admission, the patient was 
afebrile with stable vital signs. Physical examination revealed right hand paresis and abnormal 
cerebellar function, as seen with the finger-to-nose test. All laboratory results were within normal 
limits. Computed tomography (CT) with intravenous contrast of the brain and subsequent magnetic 
resonance imaging demonstrated multiple enhancing nodular densities throughout the brain, 
measuring up to 1.3 cm in maximum diameter (fig. 1). CT with intravenous contrast of the chest, 
abdomen, and pelvis revealed a 2.5 × 2.7 × 3.5-cm3 left hilar mass encasing the left upper lobe apical 
segmental artery (fig. 2) and a 2.1 × 2.1 × 2.7-cm3 medial left upper lobe mass abutting the anterior 
mediastinum. Bronchoscopic evaluation confirmed the findings of imaging studies and endobronchial 
biopsy reported typical carcinoid histology (fig. 3), with stains positive for CD56, synaptophysin, TTF-
1, and napsin, and negative for p63, CK5, and chromogranin. Ki-67 was reported at approximately 
50%. Positron emission tomography-CT of the chest (fig. 4) and somatostatin receptor scintigraphy 
(fig. 5) confirmed the presence of hypermetabolic lung masses. A CT-guided percutaneous lung 
biopsy was performed on the hilar site to confirm the diagnosis given the rarity of central nervous 
system metastasis with this histology. This report, in addition to a report from a second opinion tissue 
sample referral center, concurred with the diagnosis. The patient was placed on steroid taper and her 
metastatic brain lesions were treated with stereotactic radiosurgery (16 Gy at 60% isodense) with 
complete improvement of neurologic symptoms. Surgical evaluation deemed the patient unresectable 
and plans were made to start concurrent chemotherapy and radiation. 
Written informed consent was obtained from the patient for publication of this paper and 
accompanying images. A copy of the written consent form is available for review by the editor-in-chief 
of this journal. 
Discussion 
There are only four reported cases in the medical literature describing typical 
bronchial carcinoids metastasizing to the brain. The patients were reported in Japan, 
Israel, and Germany, and their ages ranged from 45 to 76 years [32–35].  
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Neuroendocrine tumors of the lung exist as a continuum from well-differentiated 
typical carcinoids to atypical carcinoids to extremely poorly differentiated small cell 
carcinomas. According to the 2004 WHO criteria for the diagnosis of neuroendocrine 
tumors, there are specific pathological criteria that need to be met when describing 
each subset of tumor [36] (table 1). Although metastasis of small cell carcinomas has 
been well described, little is known about the pathogenesis and presentation of typical 
bronchial carcinoid metastasis due to the very small patient population. In addition to 
exploring the tumor’s genetics and clinical tendencies, we must also understand the 
treatment modalities for this malignancy in order to ultimately improve patient 
survival. 
Researchers have suggested several mechanisms to explain bronchial carcinoids’ 
ability to metastasize, including dendritic cell apoptosis [36], deletions of 11q [37] and 
4q25 [38], DNA methylation [39], and aneuploidy DNA content [40]. Other signals or 
genes that have been implicated include cell cycle inhibitor RB1 [41], drs tumor 
suppressor gene [42], phospholipase C beta 3 [43], and apoptosis signal caspase-8 [44]. 
Markers for malignant bronchial carcinoid tumor transformation include gastrin-
releasing peptide [45], Bcl-2 [45], p53 [45], POU factor Brn3adel [46], and tyrosine 
kinase receptors c-kit, PDGFR alpha/beta, and EGFR [46, 47]. Additionally, CD44, nm23, 
and Ki-67 have all been shown to have prognostic significance for this tumor [46, 47]. 
Although the most common metastatic site of all carcinoid tumors is the liver, 
extrathoracic metastatic disease with bronchial carcinoid tumors is very rare, with one 
study citing a rate of 5% in a sample of 525 patients [1]. Most patients with bronchial 
carcinoids are asymptomatic and their diagnosis is often delayed considerably. 
Symptomatic patients can have hemoptysis from tumor hyper-vascularity or cough 
with recurrent pneumonia due to proximal airway obstruction. About three-fourths of 
bronchial carcinoids are centrally located and have a pink to red vascular mass 
appearance with intact bronchial epithelium. 
Bronchial carcinoids, in addition to Merkel cell carcinomas, pheochromocytomas, 
medullary thyroid carcinomas, and pancreatic neuroendocrine tumors, arise from 
neuroendocrine cells and have the capacity to secrete biologically active neuroamines 
and neuropeptides. Despite the fact that less than 5% of patients exhibit hormonally 
related symptoms, typical and atypical bronchial carcinoids have the potential to cause 
carcinoid syndrome and Cushing’s syndrome through ectopic production of serotonin 
[18] and adrenocorticotropic hormone [48–51], respectively. Approximately 80% of 
typical bronchial carcinoids and 60% of atypical tumors express somatostatin 
receptors and can be imaged with radiolabeled octreotide [11, 52–55]. Although this 
scan can image the entire body and identify metastatic disease outside the lung very 
easily, it has a very low specificity for disease detection [55, 56]. Currently, there are no 
screening guidelines for bronchial carcinoid tumors and their presence can only be 
identified and confirmed through the use of radiographic studies and follow-up biopsy 
with immunohistological staining of the secreted products synaptophysin, neuron-
specific enolase, and chromogranin [22]. In terms of treatment modalities, surgical 
resection with lymph node dissection offers the only chance of a cure from these 
tumors. Consensus guidelines from the National Comprehensive Cancer Network 
suggest the use of chemotherapy and radiation for resected stage II or III atypical 
carcinoids, but not for typical carcinoids [57]. Although randomized trials have 
revealed only minimal activity, metastatic bronchial carcinoid patients are often  
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treated with small cell carcinoma-related regimens including prophylactic cranial 
radiation with cisplatin plus etoposide with or without paclitaxel or single agent 
temozolomide [58]. 
Conclusion 
Although metastases to the central nervous system are very frequent with small cell 
carcinomas, their presence is very uncommon in well-differentiated neuroendocrine 
tumors such as the one we present here. This case raises questions about whether 
these tumors contain biomarkers that might predict a more aggressive behavior and if 
these patients might benefit from aggressive interventions similar to those taken in 
small cell carcinomas, such as prophylactic cranial radiation. Additionally, more data 
will need to be collected on metastatic typical bronchial carcinoid patients in order to 
better characterize the optimal radiographic and laboratory screening tests and the 
subsequent treatment modalities that will result in the best overall outcomes. 
Disclosure Statement 
The authors declare that they have no competing interests. No contributions were made nor was 
any funding provided towards this case presentation. 
 
 
 
Table 1. WHO criteria for the pathologic diagnosis of neuroendocrine tumors, updated 2004 
Typical carcinoid    Carcinoid morphology and <2 mitoses/2 mm2 (10 HPFs), lacking necrosis and 
>0.5 cm 
Atypical carcinoid    Carcinoid morphology with 2–10 mitoses/2 mm2 (10 HPFs) or necrosis (often 
punctuate) 
Large cell 
neuroendocrine 
carcinoma 
 
 
 
 
 
 
 
 
Neuroendocrine morphology (organoid nesting palisading rosettes, trabeculae) 
High mitotic rate >10/2 mm2 (10 HPFs), median of 70/2 mm2 
Necrosis (often large zones) 
Cytologic features of an NSCLC: large cell size, low nuclear to cytoplasmic ratio, 
vesicular or fine chromatin, and/or frequent nucleoli; some tumors have fine 
nuclear chromatin and lack nucleoli but qualify as NSCLC because of large cell size 
and abundant cytoplasm 
Positive immunohistochemical staining for one or more NE markers (other than 
neuron-specific enolase) and/or NE granules by electron microscopy 
Small cell 
neuroendocrine 
carcinoma 
 
 
 
 
 
Small size (generally less than the diameter of three resting lymphocytes) 
Scant cytoplasm 
Nuclei: finely granular nuclear chromatin, absent or faint nucleoli 
High mitotic rate: >11 mitoses/2 mm2 (10 HPFs), median of 80/2 mm2 (10 HPFs) 
Frequent necrosis, often in large zones 
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Fig. 1. MRI of the brain, T2 fluid-attenuated inversion recovery (FLAIR) post-contrast images, 
confirmed the presence of the lesions, measuring up to 1.3 cm in maximal diameter, with associated 
vasogenic edema in the left precentral gyrus, right occipital lobe, and bilateral frontal opercula. 
 
 
 
Fig. 2. CT with intravenous contrast of the chest, abdomen, and pelvis revealed a 3.5 cm left hilar 
mass encasing the left upper lobe apical segmental artery and 2.7 cm left upper lobe mass abutting 
the anterior mediastinum. 
 
 
 
Fig. 3. Histopathological staining revealed a neuroendocrine neoplasm with stains positive for CD56, 
synaptophysin, TTF-1, and napsin and negative for p63 and CK5. Ki-67 was reported at 
approximately 50%. 
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Fig. 4. Sagittal reconstruction shows hypermetabolic left perihilar and left upper lobe masses 
maximum standardized uptake value of 8.0. 
 
 
 
Fig. 5. Somatostatin receptor scintigraphy demonstrated moderate uptake of octreotide radiotracer 
within the left lung corresponding to the two left-sided masses seen on positron emission 
tomography-CT. 
  
Case Rep Oncol 2011;4:602–610 
DOI: 10.1159/000335557 
Published online: 
December 23, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
608 
References 
1  Quaedvlieg PF, Visser O, Lamers CB, et al: Epidemiology and survival in patients with carcinoid disease 
in The Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001;12:1295. 
2  Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934. 
3  Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic 
study from Sweden. Cancer 2001;92:2204. 
4  Hauso O, Gustafsson BI, Kidd M, et al: Neuroendocrine tumor epidemiology: contrasting Norway and 
North America. Cancer 2008;113:2655. 
5  Matilla Gonzalez J, Garcia-Yuste M, Moreno-Mata N, et al: Typical and atypical carcinoid tumors (NEC 
grades 1 and 2): prognostic factors in metastases and local recurrence (abstract). Lung Cancer 
2005;49(2 suppl):S60. 
6  Kaplan B, Stevens CW, Allen P, et al: Outcomes and patterns of failure in bronchial carcinoid tumors. Int J 
Radiat Oncol Biol Phys 2003;55:125. 
7  Zuetenhorst JM, Taal BG: Metastatic carcinoid tumors: a clinical review. Oncologist 2005;10:123. 
8  Filosso PL, Donati G, Rena O, Oliaro A: Acromegaly as manifestation of a bronchial carcinoid tumour. 
Asian Cardiovasc Thorac Ann 2003;11:189. 
9  Skuladottir H, Hirsch FR, Hansen HH, Olsen JH: Pulmonary neuroendocrine tumors: incidence and 
prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002;37:127. 
10  Gatta G, Ciccolallo L, Kunkler I, et al: Survival from rare cancer in adults: a population-based study. 
Lancet Oncol 2006;7:132. 
11  Gustafsson BI, Kidd M, Chan A, et al: Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5. 
12  Ferguson MK, Landreneau RJ, Hazelrigg SR, et al: Long-term outcome after resection for bronchial 
carcinoid tumors. Eur J Cardiothorac Surg 2000;18:156. 
13  Thomas CF Jr, Tazelaar HD, Jett JR: Typical and atypical pulmonary carcinoids: outcome in patients 
presenting with regional lymph node involvement. Chest 2001;119:1143. 
14  Cardillo G, Sera F, Di Martino M, et al: Bronchial carcinoid tumors: nodal status and long-term survival 
after resection. Ann Thorac Surg 2004;77:1781. 
15  Ducrocq X, Thomas P, Massard G, et al: Operative risk and prognostic factors of typical bronchial 
carcinoid tumors. Ann Thorac Surg 1998;65:1410. 
16  Asamura H, Kameya T, Matsuno Y, et al: Neuroendocrine neoplasms of the lung: a prognostic spectrum. 
J Clin Oncol 2006;24:70. 
17  Soga J, Yakuwa Y: Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special 
reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc 
Surg 1999;5:211. 
18  Matilla Gonzalez J, Garcia-Yuste M, Moreno-Mata N, et al: Typical and atypical carcinoid tumors (NEC 
grades 1 and 2): Prognostic factors in metastases and local recurrence (abstract). Lung Cancer 
2005;49(2 suppl):S60. 
19  Harpole DH Jr, Feldman JM, Buchanan S, et al: Bronchial carcinoid tumors: a retrospective analysis of 
126 patients. Ann Thorac Surg 1992;54:50. 
20  Fiala P, Petrásková K, Cernohorský S, et al: Bronchial carcinoid tumors: long-term outcome after surgery. 
Neoplasma 2003;50:60. 
21  Gould PM, Bonner JA, Sawyer TE, et al: Bronchial carcinoid tumors: importance of prognostic factors that 
influence patterns of recurrence and overall survival. Radiology 1998;208:181. 
22  Filosso PL, Rena O, Donati G, et al: Bronchial carcinoid tumors: surgical management and long-term 
outcome. J Thorac Cardiovasc Surg 2002;123:303. 
23  García-Yuste M, Matilla JM, Alvarez-Gago T, et al: Prognostic factors in neuroendocrine lung tumors: a 
Spanish multicenter study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the 
Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR). Ann Thorac Surg 
2000;70:258. 
24  Rea F, Rizzardi G, Zuin A, et al: Outcome and surgical strategy in bronchial carcinoid tumors: single 
institution experience with 252 patients. Eur J Cardiothorac Surg 2007;31:186. 
25  Fink G, Krelbaum T, Yellin A, et al: Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 
cases in Israel and review of 640 cases from the literature. Chest 2001;119:1647.  
Case Rep Oncol 2011;4:602–610 
DOI: 10.1159/000335557 
Published online: 
December 23, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
609 
26  Yao JC, Hassan M, Phan A, et al: One hundred years after ‘carcinoid’: epidemiology of and prognostic 
factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063. 
27  Beasley MB, Thunnissen FB, Brambilla E, et al: Pulmonary atypical carcinoid: predictors of survival in 
106 cases. Hum Pathol 2000;31:1255. 
28  Erasmus JJ, McAdams HP, Patz EF Jr, et al: Evaluation of primary pulmonary carcinoid tumors using FDG 
PET. AJR Am J Roentgenol 1998;170:1369. 
29  Kayser K, Kayser C, Rahn W, et al: Carcinoid tumors of the lung: immuno- and ligandohistochemistry, 
analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients 
treated surgically. J Surg Oncol 1996;63:99. 
30  Froudarakis M, Fournel P, Burgard G, et al: Bronchial carcinoids. A review of 22 cases. Oncology 
1996;53:153. 
31  Brokx HA, Risse EK, Paul MA, et al: Initial bronchoscopic treatment for patients with intraluminal 
bronchial carcinoids. J Thorac Cardiovasc Surg 2007;133:973. 
32  Takano S, Saitoh M, Miyasaka Y, et al: Bronchial carcinoid tumor with multiple brain metastasis. No 
Shinkei Geka 1994;22:343–348. 
33  Ohnsmann A, Sachsennheimer W: Intracerebral metastasis of a bronchial carcinoid tumor. 
Neurochirurgia 1992;35:160–162. 
34  Kon T, Hara N, Su M, et al: Multiple brain metastasis of bronchial atypical carcinoid: unusual MR imaging, 
case report. No Shinkei Geka 1997;25:815–818. 
35  Shimon I, Hadani M, Nass D, et al: Malignant bronchial carcinoid tumor metastatic to the pituitary in a 
thyroid carcinoma patient: successful treatment with surgery, radiotherapy, and somatostatin analog. 
Pituitary 2004;7:51–57. 
36  Travis WD: The concept of pulmonary neuroendocrine tumors; in Travis WD, Brambilla E, Muller-
Hermelink HK, Harris CC (eds): Pathology and Genetics: Tumors of the Lung, Pleura, Thymus, and Heart. 
Lyon, IARC Press, 2004, p 19. 
37  Katsenelson NS, Shurin GV, Bykovskaia SN, et al: Human small cell lung carcinoma and carcinoid tumor 
regulate dendritic cell maturation and function. Mod Pathol 2001;14:40–45. 
38  Zhao J, de Krijger RR, Meier D, et al: Genomic alterations in well-differentiated gastrointestinal and 
bronchial neuroendocrine tumors (carcinoids): marked differences indicating diversity in molecular 
pathogenesis. Am J Pathol 2000;157:1431–1438. 
39  Johansson M, Heim S, Mandahl N, et al: Cytogenetic analysis of six bronchial carcinoids. Cancer Genet 
Cytogenet 1993;66:33–38. 
40  Toyooka S, Toyooka KO, Maruyama R, et al: DNA methylation profiles of lung tumors. Mol Cancer Ther 
2001;1:61–67. 
41  Voortman J, Lee JH, Killian JK, et al: Array comparative genomic hybridization-based characterization of 
genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci 2000;107:13040–13045. 
42  Shimakage M, Kodama K, Kawahara K, et al: Downregulation of drs tumor suppressor gene in highly 
malignant human pulmonary neuroendocrine tumors. Oncol Rep 2009;21:1367–1372. 
43  el-Naggar AK, Ballance W, Karim FW, et al: Typical and atypical bronchopulmonary carcinoids. A 
clinicopathologic and flow cytometric study. Am J Clin Pathol 1991;95:828–834. 
44  Stålberg P, Granberg D, Carling T, et al: In situ RNA-RNA hybridization of phospholipase C beta 3 shows 
lack of expression in neuroendocrine tumors. Anticancer Res 2003;23(3B):2227–2232. 
45  Ariyoshi Y, Takahashi T, Sugio K, et al: Differential inactivation of caspase-8 in lung cancers. Cancer Biol 
Ther 2002;1:65–69. 
46  Shivapurkar N, Toyooka S, Eby MT, et al: Prognostic markers in patients with typical bronchial carcinoid 
tumors. J Clin Endocrinol Metab 2000;85:3425–3430. 
47  Leblond-Francillard M, Picon A, Bertagna X, et al: High expression of the POU factor Brn3a in aggressive 
neuroendocrine tumors. J Clin Endocrinol Metab 1997;82:89–94. 
48  Granberg D, Wilander E, Oberg K: Expression of tyrosine kinase receptors in lung carcinoids. Tumour 
Biol 2006;27:153–157. 
49  Limper AH, Carpenter PC, Scheithauer B, Staats BA: The Cushing syndrome induced by bronchial 
carcinoid tumors. Ann Intern Med 1992;117:209. 
50  Jones JE, Shane SR, Gilbert E, Flink EB: Cushing’s syndrome induced by the ectopic production of ACTH 
by a bronchial carcinoid. J Clin Endocrinol Metab 1969;29:1. 
51  DeStephano DB, Lloyd RV, Schteingart DE: Cushing’s syndrome produced by a bronchial carcinoid 
tumor. Hum Pathol 1984;15:890.  
Case Rep Oncol 2011;4:602–610 
DOI: 10.1159/000335557 
Published online: 
December 23, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
 
610 
52  Scanagatta P, Montresor E, Pergher S, et al: Cushing’s syndrome induced by bronchopulmonary 
carcinoid tumors: a review of 98 cases and our experience of two cases. Chir Ital 2004;56:63. 
53  Granberg D, Sundin A, Janson ET, et al: Octreoscan in patients with bronchial carcinoid tumours. Clin 
Endocrinol 2003;59:793. 
54  Reubi JC, Kvols LK, Waser B, et al: Detection of somatostatin receptors in surgical and percutaneous 
needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969. 
55  Weiss M, Yellin A, Husza’r M, et al: Localization of adrenocorticotropic hormone-secreting bronchial 
carcinoid tumor by somatostatin-receptor scintigraphy. Ann Intern Med 1994;121:198. 
56  Yellin A, Zwas ST, Rozenman J, et al: Experience with somatostatin receptor scintigraphy in the 
management of pulmonary carcinoid tumors. Isr Med Assoc J 2005;7:712. 
57  National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (accessed on 
August 22, 2011). 
58  Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of 
advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986–2991. 